Company intelligence / Profile preview

B·R·A·H·M·S

Hennigsdorf, Brandenburg, Germanyjohannesbrahms.org ↗

Ownership: Private
Employees: ~400
Development stage: Commercial

Overview

B.R.A.H.M.S. is best known for its commercialized Procalcitonin (PCT) test for early diagnosis and monitoring of sepsis—a gold standard in Europe—and has a strong pipeline of diagnostic assays targeting infectious and critical care indications. The company’s products are distributed globally and are leaders in their specialized markets[1][2][3].

Therapeutic areas: PulmonologyInfectious DiseasesEndocrinologyOncologyImmunologyOtherCardiovascularWomen's Health
Modalities: Diagnostic testBiomarker assay
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

procalcitonin

Commercial

Indications: Sepsis

Beyond the preview

Go deeper on B·R·A·H·M·S.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B·R·A·H·M·S.

Explore the full profile